Macular Degeneration Research
Judit Baffi, M.D., Ph.D.
University of Kentucky
Title: CCR3 biology and imaging applied to CNV in AMD
Non-Technical Title: A New Molecular Target for Diagnosing the Wet Form of AMD
Duration: April 1, 2010 - June 25, 2012
Award Type: Standard
Award Amount: $100,000
We are pursuing the combined goals of understanding the role and impact of CCR3 function during blood vessel development in the eye. Further, we are exploiting CCR3 to create images of the earliest stages of neovascular, ‘wet’, age-related macular degeneration (AMD). We are achieving this by using multiple molecular, biological, and genetic approaches. The potential impact of this proposal is very high as it will further define the functional relevance of the CCR3/eotaxin “axis” to the clinical development and progression of AMD. This will lead to the development of novel CCR3-targeting diagnostic and therapeutic strategies that can be used in the clinic to detect the subclinical stages of neovascular AMD, thus preventing this disease from progressing into a vision threatening state.
Age-related macular degeneration (AMD) is a debilitating eye disease which mostly impacts people over age 55 years. It is the leading cause of blindness in the industrialized world. It comes in two varieties, "dry" AMD and "wet" AMD. What distinguishes the wet form from the dry form is the growth of new, leaky, blood vessels under central portion of the retina, which is responsible for your vision as it contains your photoreceptors. The wet form of AMD has a more rapid progression of visual decline which leads to difficulties with basic daily activities such as writing, reading and driving and will often lead to legal blindness. There are some medications currently in use that can slow or stop the progression of this form of the disease once it has become symptomatic, however none of these treatments can prevent the initial vision loss associated with this disease.
Recently our research group identified a molecule known as CCR3 which is located only on AMD related blood vessels.
One of our goals is to determine the origin of these cells, using this marker, which contribute to the growth of these abnormal blood vessels in the eye so we can pick an optimal delivery mechanism for targeting these vessels. The other goal is to develop a minimally invasive novel imaging technique, in animal models of AMD, which would allow us to detect these blood vessels and diagnose and treat this disease before it causes any damage to the retina that would lead to vision loss.
Once this diagnostic and therapeutic treatment has been developed in animal models and its safety has been confirmed then it can be further tested for efficacy in clinical trials on people.